PMID- 20809107
OWN - NLM
STAT- MEDLINE
DCOM- 20110328
LR  - 20211020
IS  - 1473-4230 (Electronic)
IS  - 1473-4222 (Linking)
VI  - 9
IP  - 4
DP  - 2010 Dec
TI  - Difference in the effects of tandospirone on ataxia in various types of 
      spinocerebellar degeneration: an open-label study.
PG  - 567-70
LID - 10.1007/s12311-010-0199-0 [doi]
AB  - The aim of this study was to investigate the effects of tandospirone on ataxia in 
      various types of spinocerebellar degeneration (SCD). Fifteen milligram per day of 
      tandospirone was administered to 39 patients with SCD (spinocerebellar atrophy 
      (SCA) 1, five patients; SCA2, six patients; Machado-Joseph disease (MJD), 14 
      patient; SCA6, five patients; multiple system atrophy-cerebellar type (MSA-C), 
      seven patients; and multiple system atrophy-Parkinson type (MSA-P), two 
      patients). All patients were assessed before and 4 weeks after administration of 
      the drug using the international cooperative ataxia rating scale total score 
      (ARS), total length traveled (TLT) of body stabilometry, and a self-rating 
      depression scale. Statistically, ARS showed a significant difference in MJD 
      (p = 0.005) and SCA6 (p = 0.043). TLT also showed a significant difference in MJD 
      (p = 0.002) and SCA6 (p = 0.043). Eight of 39 patients (SCA1, 1/5; SCA2, 0/6; 
      MJD, 4/14; SCA6, 3/5; MSA-C, 0/7; and MSA-P, 0/2) showed more than a five point 
      reduction in ARS, and 13 of 39 patients (SCA1, 0/5; SCA2, 1/6; MJD, 8/14; SCA6, 
      4/5; MSA-C, 0/7; and MSA-P, 0/2) showed a reduction of TLT. Our data indicate 
      that the effects of tandospirone on ataxia are different between types of SCD. 
      Therefore, tandospirone is useful for cerebellar ataxia in patients with MJD and 
      SCA6.
FAU - Takei, Asako
AU  - Takei A
AD  - Hokuyukai Neurology Hospital, Niju-yon-ken 2-2-4-30, Nishi-ku, Sapporo, 063-0802, 
      Japan. atakei@med.hokudai.ac.jp
FAU - Hamada, Shinsuke
AU  - Hamada S
FAU - Homma, Sanae
AU  - Homma S
FAU - Hamada, Keiko
AU  - Hamada K
FAU - Tashiro, Kunio
AU  - Tashiro K
FAU - Hamada, Takeshi
AU  - Hamada T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Cerebellum
JT  - Cerebellum (London, England)
JID - 101089443
RN  - 0 (Isoindoles)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 190230I669 (tandospirone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Ataxia/*drug therapy/*etiology
MH  - Depression/chemically induced
MH  - Female
MH  - Humans
MH  - Isoindoles/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Pyrimidines/adverse effects/*therapeutic use
MH  - Serotonin Receptor Agonists/adverse effects/*therapeutic use
MH  - Spinocerebellar Degenerations/classification/*complications
EDAT- 2010/09/03 06:00
MHDA- 2011/03/29 06:00
CRDT- 2010/09/03 06:00
PHST- 2010/09/03 06:00 [entrez]
PHST- 2010/09/03 06:00 [pubmed]
PHST- 2011/03/29 06:00 [medline]
AID - 10.1007/s12311-010-0199-0 [doi]
PST - ppublish
SO  - Cerebellum. 2010 Dec;9(4):567-70. doi: 10.1007/s12311-010-0199-0.